Rangering i aksjer
#32515
Pharmena S.A. engages in the sale of dietary supplements in Poland and... Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. It also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, the company is involved in research and development of therapeutic applications of 1 MNA as an anti-inflammatory and anti-fibrotic drug; and research and development at pulmonary fibrosis, respiratory tract infections, including viral infections, COVID-19, inflammatory diseases, metabolic diseases and other therapeutic applications. Pharmena S.A. was founded in 2002 and is based in Lódz, Poland. Pharmena S.A. operates as a subsidiary of Pelion S.A.
Handel Pharmena S.a. (PHR)
Pris PHR pris med markedsverdi på B
Markedsverdi av Pharmena S.a.(PHR)
Markedsverdi: $9.88M
Per August 2026 har Pharmena S.a. en markedsverdi på $9.88M. Dette gjør Pharmena S.a. til det 32515th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Pharmena S.a. fra 2008 til 2026
PHR sammenlignet med topp 5 mest populære stocks
| Pris på PHR |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.460T
|
+55,281,968.54%
|
|
|
|
|
$4.489T
|
+45,454,407.56%
|
|
|
|
|
$4.141T
|
+41,925,023.08%
|
|
|
|
|
$3.569T
|
+36,130,097.11%
|
|
|
|
|
$2.798T
|
+28,328,999.74%
|
